Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how to anticipate and prepare for new IP, legal, and regulatory developments.
- Building Uniquity Bio: Teams, Capital, And Strategy
- A Better Way For BD And Commercial Teams To Evaluate Strategic Assets
- Adapting To Change In The Era Of Tariffs, Tax And Regulatory Changes
- Why Empathy Is Your Most Powerful Leadership Tool
- Essential Medicines And The Need For A Robust U.S. Supply Chain
- Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
- Borrowed Brilliance: Is Pharma Becoming Overly Reliant On Acquisitions?
- Securing Capital At The Right Moment: How Much Should Startups Ask For?
COMPANIES TO WATCH
-
![Stacy Lindborg_Imunon]( "Companies To Watch: Imunon")
Companies To Watch: ImunonImunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer.
-
![Tim Lu_Senti Bio]( "Companies To Watch: Senti Bio")
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.
-
![Amy Burroughs_Terns Pharmaceuticals]( "Companies To Watch: Terns Pharmaceuticals")
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
-
![Dr-Stella-Sarraf_Spinogenix]( "Companies To Watch: Spinogenix")
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
WHERE ARE THEY NOW
-
![Bobak Azamian]( "Where Are They Now? Tarsus Pharmaceuticals")
Where Are They Now? Tarsus PharmaceuticalsTarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
-
![Teva Cover]( "Where Are They Now? Teva Pharmaceuticals")
Where Are They Now? Teva PharmaceuticalsTeva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
![Ironwood Cover_2016]( "Where Are They Now? Ironwood Pharmaceuticals")
Where Are They Now? Ironwood PharmaceuticalsIronwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
NEWSLETTER ARCHIVE
- 05.08.25 -- Ramp Up Your Recruitment Efforts With RWD
- 05.07.25 -- The Implications Of China's Growing Biotech Industry
- 05.05.25 -- Is Pharma Becoming Overly Reliant On Acquisitions?
- 05.02.25 -- How To Be A CFO With Insmed's Sara Bonstein
- 05.02.25 -- New Podcast Episodes: China's Growth, Investment Trends, NIH Cuts, and more
SPOTLIGHT
Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.
